In 1997, Bristol-Myers Squibb  opened a 433-acre research campus in Hopewell, New Jersey. Two important new medicines co-developed with Sanofi-Sythelabo received approvals: AVAPRO (irbesartan) and PLAVIX (clopidogrel bisulfate).PLAVIX would become the company’s leading product.

In 2016, Bristol-Myers Squibb announced plans to close its 433-acre campus in Hopewell Township by 2020, while adding to two of its other sites in central New Jersey.